Spatial Multiomics Reveal Insights Into ADC Efficacy

Goni O, Klümper N, Muniz Moreno MdM, Eckstein M, Kuppe C (2026)


Publication Type: Journal article

Publication year: 2026

Journal

Book Volume: 56

Article Number: e70190

Journal Issue: 5

DOI: 10.1002/eji.70190

Abstract

Antibody–drug conjugates (ADCs) have transformed the therapeutic landscape of solid tumors; however, responses remain heterogeneous and complex to predict. In addition, a growing number of multiple ADC targets are either approved or in late-stage clinical development, such as NECTIN-4, HER2, or TROP2 for metastatic urothelial cancer. Spatial multiomics—representing next-generation methods that couple high-plex RNA sequencing and multiplex protein imaging with precise x-y-z coordinates within tissues—offer a direct way to correlate (ADC) antigen expression, cell state information, and micro-anatomical context with patient treatment outcomes. In this review, we highlight suitability and technological advancements in current spatial transcriptomics and proteomics approaches to decode modes of action and resistance to ADCs and extract biological insights, particularly in metastatic urothelial cancer—and propose an integrative framework that combines spatial readouts with machine and/or deep learning-driven analytics to stratify patients, forecast on- and off-target toxicities, and guide next-generation linker–payload designs or combination therapies.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Goni, O., Klümper, N., Muniz Moreno, M.d.M., Eckstein, M., & Kuppe, C. (2026). Spatial Multiomics Reveal Insights Into ADC Efficacy. European Journal of Immunology, 56(5). https://doi.org/10.1002/eji.70190

MLA:

Goni, Osman, et al. "Spatial Multiomics Reveal Insights Into ADC Efficacy." European Journal of Immunology 56.5 (2026).

BibTeX: Download